Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001727317
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing?

LIVE TEST

Submission Contact Information

Name Phone

E-Mail Address

144: Issuer Information

Name of Issuer Arcturus Therapeutics Holdings Inc.

SEC File Number 001-38942

10628 SCIENCE CENTER DRIVE

SUITE 250 SAN DIEGO

Address of Issuer SAN DIEGO CALIFORNIA

92121

Phone 8589002660

Name of Person for Whose Account the Securities are To Be Sold Chivukula Pad

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

144: Securities Information

| Title of the Class of Securities To Be Sold | Name and Address of the Broker | Number of Shares or Other Units To Be Sold | Aggregate Market Value | | | Name the Securities Exchange |
|--|---|---|---------------------------|----------|------------|------------------------------------|
| Arcturus Therapeutics Holdings Inc | Merrill Lynch Pierce Fenner & Smith 100 Federal St 12th Floor Boston MA 02110 | 17075 | 512287.00 | 26555483 | 05/10/2023 | NASDAQ |

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

| Title of the Class | Date you Acquired | Nature of Acquisition Transaction | Name of Person from Whom Acquired | Is this a Gift? | Date Donor Acquired | Amount of Securities Acquired | Date of Payment | Nature of Payment * |
|-----------------------|----------------------|-----------------------------------|--|--------------------------|---------------------------|-------------------------------------|--------------------|---------------------|
| Common | 04/03/2013 F | Founders Shares | Arcturus Therapeutics Holdings Inc | | | 17075 | 04/03/2013 ca | ash |

^{*} If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

| Name and Address of Seller | Title of Securities Sold | Date of Sale | Amount of Securities Sold | Gross Proceeds |
|--|------------------------------------|-----------------|---------------------------------|----------------|
| Padmanabh Chivukula c/o Arcturus Therapeutics Holdings Inc 10628 Science Center Drive Suite 250 San Diego CA 92121 | Arcturus Therapeutics Holdings Inc | 05/01/2023 | 5000 | 129390.80 |
| Padmanabh Chivukula c/o Arcturus Therapeutics Holdings Inc 10628 Science Center Drive Suite 250 San Diego CA 92121 | Arcturus Therapeutics Holdings Inc | 04/03/2023 | 5000 | 126663.24 |
| Padmanabh Chivukula c/o Arcturus Therapeutics Holdings Inc 10628 Science Center Drive, Suite 250 San Diego CA 92121 | Arcturus Therapeutics Holdings Inc | 03/01/2023 | 5000 | 79085.58 |

144: Remarks and Signature

Remarks

Date of Notice 05/10/2023
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1 12/05/2022

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Padmanabh Chivukula

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)